Amplia Therapeutics Limited
INNMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$41.06M
Close$
$0.04
25.3% downside
Current Fair Value
25.3% downsideOvervalued by 25.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $41.06 Million |
|---|---|
| Enterprise Value | $13.50 Million |
| Earnings per Share | $-0.02 |
| Beta | -0.42 |
| Outstanding Shares | 513,071,629 |
Return
| Return on Equity | -35.68% |
|---|---|
| Return on Assets | -33.98% |
| Return on Invested Capital | -50.14% |
Valuation & Multiples
| P/E Ratio | -4.79 |
|---|---|
| PEG | 81.6 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.57 |
| Enterprise Value to EBIT | -0.68 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Next Earnings Call
Expected Date
November 27, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Amplia Therapeutics Limited
8 employees
CEO: Christopher J. Burns
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an i...